Ginger effect on chemotherapy-induced neuropathy
Phase 2
- Conditions
- Condition 1: ovarian cancer. Condition 2: lung cancer.Malignant neoplasm of ovaryMalignant neoplasm of bronchus and lung
- Registration Number
- IRCT2013121415780N1
- Lead Sponsor
- Drug Applied Research Center, Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Inclusion Criteria:suffering from ovarian cancer; non-small cell lung cancer; willingness to corporate.
Exclusion Criteria
age more than 70 years; suffering from diabetes; AIDS;hyperthyroidism; primary neurological diseases; other kinds of malignancies; history of chemotherapy; consumption of vitamin; mineral or fish oil supplementation at list 3 months before the enrollment; Ginger sensitivity
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of chemotherapy-induced peripheral neuropathy. Timepoint: before the onset of chemotherapy and after 18 weeks, at the end of the treatment period. Method of measurement: rTNS Score, Nerve Conduction Studiy.;Severity of chemotherapy-induced peripheral neuropathy. Timepoint: before the onset of chemotherapy and after 18 weeks, at the end of the treatment period. Method of measurement: rTNS Score, Nerve Conduction Studiy.
- Secondary Outcome Measures
Name Time Method Serum levels of pro-inflammatory cytokines. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: ELISA.;Total Antioxidant Status (TAS). Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.;Serum level of MDA. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.;Activity of SOD & GPX enzymes in RBC. Timepoint: before the onset of chemotherapy and after 18 weeks at the end of treatment. Method of measurement: Spectrophotometry.